Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00023972 · ClinicalTrials.gov registry record · Phase 3
Gemcitabine With or Without Exatecan Mesylate in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
A Phase 3 study, sponsored by Daiichi Sankyo.
- Completed
- Registry status
- Phase 3
- Development phase
NCT00023972: Completed Phase 3 study, sponsored by Daiichi Sankyo.
NCT00023972 is a Phase 3 study that has completed, run by Daiichi Sankyo. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00023972, a Phase 3 study, has completed, sponsored by Daiichi Sankyo.
- COMPLETED
- Registry status
- Phase 3
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known if gemcitabine is more effective with or without exatecan mesylate in treating pancreatic cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of gemcitabine alone to that of gemcitabine and exatecan mesylate in treating patients who have locally advanced or metastatic pancreatic cancer.
Interventions
- DRUG gemcitabine hydrochloride
- DRUG exatecan mesylate
Trial Details
| Field | Value |
|---|---|
| Start Date | 2001-07 |
| Est. Completion | 2005-04 |
| Phase | Phase 3 |
What the finished NCT00023972 record still lists
NCT00023972 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 2 interventions - of which gemcitabine hydrochloride is the first listed.
NCT00023972 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00023972 about?
NCT00023972 is a clinical study titled "Gemcitabine With or Without Exatecan Mesylate in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known if gemcitabine is more effective with or without exatecan mesylate in treating pancreatic cancer. PURPOSE: Randomized phase III trial to compare the effectiven...
What is the current status of trial NCT00023972?
This trial is currently completed. It is a Phase 3 study. The study started on 2001-07. Estimated completion is 2005-04.
What interventions are being tested in trial NCT00023972?
The interventions under investigation include: gemcitabine hydrochloride (DRUG), exatecan mesylate (DRUG).
Who is sponsoring clinical trial NCT00023972?
This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia